We examined activated partial thromboplastin time, kaolin clotting time, mixing with normal plasma in kaolin clotting time, dilute Russell's viper venom time, dilute Russell's viper venom time at high lipid concentrations, antiphospholipid antibodies, and anti-cardiolipin-&beta;2-glycoprotein I complex antibody in 135 patients with prolongation of activated partial thromboplastin time and diagnosed 86 patients positive for lupus anticoagulant. The sensitivity of activated partial thromboplastin time and dilute Russell's viper venom time/dilute Russell's viper venom time-high lipid concentrations ratio for lupus anticoagulant were markedly high, but the specificity of activated partial thromboplastin time for lupus anticoagulant was not markedly high. The specificity, but not the sensitivity, of kaolin clotting time-mixing with normal plasma in kaolin clotting time was markedly high. In summary, dilute Russell's viper venom time to dilute Russell's viper venom time-high lipid concentrations ratio gave high sensitivity as well as specificity, being the only assay to confirm this. Of the patients positive for lupus anticoagulant, 25% were positive for anti-phospholipid antibodies and 17% were positive for anti-cardiolipin-&beta;2-glycoprotein I complex antibody. Of the lupus anticoagulant-positive patients with thrombosis, 45% were positive for anti-phospholipid antibodies, 35% were positive for anti-cardiolipin-&beta;2-glycoprotein I complex antibody, 60% were positive for both anti-phospholipid antibodies and anticardiolipin-&beta;2-glycoprotein I complex antibody, and only 17% were negative for anti-phospholipid antibodies and anticardiolipin-&beta;2-glycoprotein I complex antibody. These findings suggest that lupus anticoagulant can be diagnosed by dilute Russell's viper venom time/dilute Russell's viper venom time-high lipid concentrations ratio, and that thrombosis in lupus anticoagulant-positive may be predictable from both anti-phospholipid antibodies and anti-cardiolipin-&beta;2glycoprotein I complex antibody. Plasma tissue type plasminogen activator level in lupus anticoagulant patients was significantly increased, and plasma tissue type plasminogen activator and fibrin-D-dimer levels in lupus anticoagulant-positive patients with thrombosis were significantly higher than in those without thrombosis, suggesting that the diagnosis of thrombosis by hemostatic markers might be important in lupus anticoagulant.
Summary: We examined activated partial thromboplastin time, kaolin clotting time, mixing with normal plasma in kaolin clotting time, dilute Russell's viper venom time, dilute Russell's viper venom time at high lipid concentrations, antiphospholipid antibodies, and anti-cardiolipin-&beta;2-glycoprotein I complex antibody in 135 patients with prolongation of activated partial thromboplastin time and diagnosed 86 patients positive for lupus anticoagulant. The sensitivity of activated partial thromboplastin time and dilute Russell's viper venom time/dilute Russell's viper venom time-high lipid concentrations ratio for lupus anticoagulant were markedly high, but the specificity of activated partial thromboplastin time for lupus anticoagulant was not markedly high. The specificity, but not the sensitivity, of kaolin clotting time-mixing with normal plasma in kaolin clotting time was markedly high. In summary, dilute Russell's viper venom time to dilute Russell's viper venom time-high lipid concentrations ratio gave high sensitivity as well as specificity, being the only assay to confirm this. Of the patients positive for lupus anticoagulant, 25% were positive for anti-phospholipid antibodies and 17% were positive for anti-cardiolipin-&beta;2-glycoprotein I complex antibody. Of the lupus anticoagulant-positive patients with thrombosis, 45% were positive for anti-phospholipid antibodies, 35% were positive for anti-cardiolipin-&beta;2-glycoprotein I complex antibody, 60% were positive for both anti-phospholipid antibodies and anticardiolipin-&beta;2-glycoprotein I complex antibody, and only 17% were negative for anti-phospholipid antibodies and anticardiolipin-&beta;2-glycoprotein I complex antibody. These findings suggest that lupus anticoagulant can be diagnosed by dilute Russell's viper venom time/dilute Russell's viper venom time-high lipid concentrations ratio, and that thrombosis in lupus anticoagulant-positive may be predictable from both anti-phospholipid antibodies and anti-cardiolipin-&beta;2glycoprotein I complex antibody. Plasma tissue type plasminogen activator level in lupus anticoagulant patients was significantly increased, and plasma tissue type plasminogen activator and fibrin-D-dimer levels in lupus anticoagulant-positive patients with thrombosis were significantly higher than in those without thrombosis, suggesting that the diagnosis of thrombosis by hemostatic markers might be important in lupus anticoagulant. Key Words: Lupus anticoagulant&mdash;Kaolin clotting time&mdash;Dilute Russell's viper venom time&mdash;Anticardiolipin an-tibody&mdash;Anti-cardiolipin-&beta;2 glycoprotein I complex antibody.
Lupus anticoagulants (LAs) were initially noted to be associated with systemic lupus erythematosus (SLE) ( 1 ). However, they have now been described in a number of other pathologic conditions, as well as in apparently normal subjects (2) . In recent years, it has become clear that the presence of LA is a risk factor for thrombosis (3, 4) , recurrent spontaneous abortion (5), thrombocytopenia, and a variety of neurologic disorders. Lupus anticoagulants are immunoglobulins that interfere with a variety of coagulation assays, prolonging phospholipid-dependent coagulation tests (6) (7) (8) . Their anticoagulant property is essentially an in vitro phenomenon. However, the mechanism of the thrombosis in patients positive for LA is still not clear, although it has been speculated that it is caused by the suppression of prostaglandin 12 synthesis in vascular endothelial cells (9), by hypofibrinolysis (10) , or by the suppression of activation of protein C ( 11, 12) . Diagnosis of LA has been made from activated partial thromboplastin time (APTT) (13), kaolin clotting time (KCT) (14) , and dilute Russell's viper venom time (DRVVT) (8, 15) , but the reports of the sensitivity for LA differ substantially (7) . An anti-phospholipid antibody (APA) family of antibodies (IgG, IgM, IgA) includes: LA or anti-cardiolipin antibodies (ACA) (16) , antibodies to various negatively charged phospholipids (antiphosphatidyl serines), antibodies to neutral phospholipids (anti-phosphatidyl-ethanolamine), as well as complexes of phospholipids and proteins [cardiolipin-p2-glycoprotein I (p2-GPI)-complex antibody] (ACL-p2-GPIA) (17) . We examined the sensitivity and specificities of these tests in patients suspected to be LA positive, and also determined the relationship between thrombosis and the diagnostic methods for LA or APA.
MATERIALS AND METHODS
We examined 135 patients with prolongation of APTT who were consulted to our laboratory for 5 years as shown in Table 1 . Of these, 86 patients were positive for LA and the remaining 49 were negative. The mean age of LA-positive patients was 43.1 years, plus or minus 19.5 years; 27 were male and 59 were female. The underlying diseases were SLE (n = 18), idiopathic thrombocytopenic purpura (ITP; n = 13), and malignant diseases (n = 12). Of the 86 LA-positive patients, 20 patients had associated thrombosis ( Table 2 ). We also examined 67 patients with ITP without prolongation of APTT, and 20 healthy volunteers as controls. Of the 20 LA-positive patients with associated thrombosis, there were eight cases of cerebral thrombosis, seven deep vein thrombosis, two acute myocardial infarction, two pulmonary embolism, two foot artery thrombosis, two Budd-Chiari syndrome, and one retinal vein occlusion. Associated thrombosis was also observed in five patients negative for LA; these patients were immediately treated with anticoagulant, antiplatelet, or fibrinolytic agents. After improvement of the symptoms and temporary withdrawal of the drug, blood samples were obtained from these patients. No patients were treated with anticoagulants at the time of blood sampling. Lupus anticoagulant was considered to be positive if at least two of the following three criteria were fulfilled: Blood was collected by venipuncture by mixing nine parts of whole blood with one part of 3.8% trisodium citrate. Activated partial thromboplastin time was determined by Langdell's method (18) . For determination of APTT-1, we used Thrombofax (Ortho D.S., Raritan, NJ, USA), and for APTT-2, we used Actin (DADE Co., Mi- ami, FL, USA) as partial thromboplastin. Prothrombin time (PT) was determined by the one-stage method described by Quick et al. (19) . Simplastin (Organon Teknika, Turnhout, Belgium) was used as tissue thromboplastin. Kaolin clotting time was examined as follows: 0.2 mL of plasma was incubated with 0.1 mL of kaolin (Behringwerke AG, Marburg, Germany) (20 mg/mL), and clotting time was measured after adding 0. (ELISA) kit (Yamasa Co., Tokyo, Japan). Antithrombin activity and protein C activity were measured by an amidolytic assay, using Berichrom-Protein C (Behringwerke AG) and Berichrom AT III (Behringwerke AG), respectively. Protein C and protein S antigens were measured by ELISA, using respective polyclonal antibodies (Dakopatts, Hagersten, Denmark). Thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), FDP-D-dimer, tissue type plasminogen activator (t-PA), and plasminogen activator inhibitor-I (PAI-1) antigens were determined using Enzygnost-TAT (Behringwerke AG), PIC-test-Kokusai (Kokusai-siyaku, Koube, Japan), Frelisa D-dimer (Agen, Brisban, Australia), onestep sandwich ELISA t-PA (Fuzirebio, Tokyo, Japan), and ImulyseTM PAI-I (Biopool AB, Umea, Sweden), respectively. The data are shown as means plus or minus SD, and statistical analysis was performed using Student t test. P values of < 0.05 were considered to be significant.
RESULTS
In coagulation tests, APTT-1 and APTT-2 in patients with prolongation of APTT were significantly longer than those in patients with ITP (negative for LA) and healthy volunteers (P < 0.01, respectively), but there were no significant differences in PT among the four groups. Dilute Russell's viper venom time and KCT in patients with prolongation of APTT were significantly longer than those in healthy volunteers (P < 0.01). There were no significant differences in DRVVT, KCT, or KCT-MIX between patients with prolongation of APTT negative for LA and ITP patients negative for LA. In patients positive for LA, the DRVVT/DRVVT-HLC ratio was significantly higher and KCT-MIX was significantly longer compared to LA-negative patients with prolongation of APTT, ITP, and healthy volunteers ( Table 3 ). In KCT-MIX of LA-positive patients, 6 patients with thrombosis and 30 patients without thrombosis were negative. Although all patients negative for LA except coagulation factor deficiency were negative for KCT-MIX, more than half of the patients with coagulation factor deficiency were positive for KCT-MIX ( Fig.   1 ). Only one LA-positive patient with thrombosis and nine LA-positive patients without thrombosis had negative DRVVT/DRVVT-HLC ratios, and none of the patients negative for LA had positive ratios (Fig. 2 ). The sensitivity of APTT-1 and DRVVT/DRVVT-HLC ratio for LA was markedly high but the specificity of APTT-1 I for LA was not markedly high. The specificity of KCT-MIX was high, but its sensitivity was not markedly high. Both sensitivity and specificity of DRVVT/DRVVT-HLC ratio were remarkably high (Table 4 ). Of the patients with prolongation of APTT except those with coagulation factor deficiency, liver diseases, or undergoing warfarin therapy, APA was positive in 25% of those positive for LA and in 18% of those negative for LA, whereas ACL-P2-GPIA was positive in 17% of patients positive for LA and in 0% of patients negative for LA. Forty-five percent of LA-positive patients with thrombosis were positive for APA, and 35% were positive for ACL-r32-GPIA (Table 5 ). The plasma ACL-(32-GPIA level in patients with thrombosis was significantly higher than that in those without thrombosis ( Fig. 3 ) and APA was slightly higher in LA patients without thrombosis (Fig. 4 ). Sixty percent of patients positive for both APA and ACL-r32-GPIA had associated with thrombosis, but only 17% of those negative for both APA and ACL-p2-GPIA were associated with thrombosis. Antiphospholipid antibody and ACL-(32-GPIA correlated well with DRVVT/DRVVT-HLC ratio and KCT-MIX, especially in patients with thrombosis (Table 5 ). Of the hemostatic markers, plasma thrombin antithrombin complex (TAT), plasmin-antiplasmin complex (PAP), fibrin-D-dimer, and plasminogen activator inhibitor-I (PAI-1) in both LA-positive and LA-negative patients were significantly higher than those in normal volunteers. Plasma t-PA level in LA-positive patients was significantly higher than in LA-negative patients and normal volunteers (P < 0.01). Plasma protein C activities in both LApositive and LA-negative patients were slightly reduced ( Table 6 ). There were no significant differences in plasma TAT, PAP, PAI-1, antithrombin activity, protein C activity, or protein S antigen levels between patients positive for LA and those negative. Plasma t-PA and D-dimer levels in LA-positive patients with thrombosis were significantly higher than those without thrombosis (Table 7) (P < 0.01 and P < 0.05, respectively). ACL-r32-GPIA. anti-cardiolipin-¡32-glycoprotein I complex antibody ; APA; anti-phospholipid antibody; APTT, activated partial thromboplastin time; DRVVT, dilute Russell's viper venom time; HLC, high lipid concentration; KCT, kaolin clotting time; KCT-Mix, mixing with normal plasma in kaolin clotting time. ACL-¡3-GPIA, anticardiolipin-(32-glycoprotein I complex; APA, antiphospholipid antibody; LA, lupus anticoagulant.
DISCUSSION
Diagnosis of LA has been performed by various clotting time methods, the sensitivities of which depend on the amount or nature of the phospholipids involved (7, 20) . The sensitivity for LA is thought to be negatively correlated with the concentration of phosphatidylserine (21) . Our findings reported here showed that the differences between APTT-1 and APTT-2 in patients positive for LA were as great as those between DRVVT and DRVVT-HLC, indicating that Thrombofax is sensitive for LA and that Actin is not. The APTT determined by Thrombofax, KCT, and DRVVT may be a sensitive marker for LA. There were no significant differences in DRVVT, KCT, and KCT-MIX between patients with prolongation of APTT negative for LA and ITP patients negative for LA. Because some autoantibodies including anti-platelet antibody exist in ITP patients, LA is often associated with ITP. Because the phospholipid plays no TABLE 6. Hemostatic abnormalities in patients with prolongation of activated partial thromboplastin time tP<0.01. APTT, activated partial thromboplastin time; LA, lupus anticoagulants ; PAI-1, plasminogen activator inhibitor I; PAP, plasminantiplasmin complex; TAT, thrombin-antithrombin complex; t-PA, tissue type plasminogen activator. role in the KCT assay, the KCT-MIX is more sensitive than APTT for detecting LA. Kaolin clotting time-MIX was significantly prolonged compared to LA-negative patients with prolongation of APTT, ITP, and healthy volunteers. However, KCT-MIX was negative in 30 LApositive patients without thrombosis and positive in more than half of the patients with coagulation factor deficiency. Dilute Russell's viper venom time/DRVVT-HLC ratio was significantly high in patients positive for LA, and was negative in only one LA-positive patient with thrombosis and nine LA-positive patients without thrombosis. None of the patients negative for LA showed positive DRVVT/DRVVT-HLC ratios. Russell viper venom used in DRVVT directly activates factor X and generates thrombin without the effects of factor VIII, IX, or XI, and may be specific to LA except factor V inhibitor (8) . Under our experimental conditions, the sensitivity of APTT-1 and DRVVT/DRVVT-HLC ratio for LA were markedly high, but the specificity of APTT-1 for LA was not markedly high. The specificity of KCT-MIX was high, but the sensitivity of KCT-MIX was not markedly high. Both sensitivity and specificity of DRVVT/ DRVVT-HLC ratio were markedly high. Of the patients with prolongation of APTT, APA was positive in 25% of those positive for LA, and ACL-P2-GPIA was positive in 17% and 0% of those positive and negative for LA, respectively. Anti-phospholipid antibody is frequently positive in LA patients, and increased APA is considered to be a risk factor of thrombosis (22) . Our findings showed that of LA-positive patients with thrombosis, 45% were positive for APA and 35% were positive for ACL-(32-GPIA. Because the sensitivity of APA for thrombosis was not markedly high, it is considered that the measured APA in LA requires p2GPI as a cofactor for cardiolipin (23) . The plasma ACL-~2-GPIA level in patients with thrombosis was significantly higher than that in those without thrombosis. Patients who were positive for both ACA and ACL-r32-GPIA frequently had associated thrombosis, but those negative for both APA and ACL-(32-GPIA showed less associated thrombosis.
It is recommended that young patients with thrombosis from unknown causes be analyzed with respect to both APA and ACL-(32-GPIA. ACA and ACL-~i2-GPIA both correlated well with DRVVT/DRVVT-HLC ratio and KCT-MIX, especially in patients with thrombosis. Of the hemostatic markers examined, plasma TAT, PAP, fibrin-D-dimer, and PAI-I in both LA-positive and LA-negative patients were significantly high, suggesting that these patients were in a hypercoagulable state. LA-negative patients also showed associated thrombosis. Plasma protein C activity was slightly reduced in both LA-positive and LA-negative patients. Reduced plasma protein C and increased plasma activated protein C-protein C inhibitor complex have been reported previously in patients with LA (24) and disseminated intravascular coagulation (25) . These hemostatic abnormalities may not be specific for LA. In the present study, plasma t-PA levels in LApositive patients were significantly higher than in LAnegative patients and normal volunteers. Plasma t-PA is released from vascular endothelial cells and causes fibrinolysis (26) , and an increased plasma t-PA level has been shown to reflect vascular endothelial cell injury (27) . In LA-positive patients, plasma t-PA and D-dimer levels in those with thrombosis were significantly higher than in those without thrombosis, suggesting that increased t-PA and fibin-D-dimer might predict the association of thrombosis. Increased plasma fibrin-D-dimer is caused by thrombosis; however, increased plasma t-PA level is reflected in vascular endothelial cell injury, suggesting that LA is associated with vascular endothelial cell injury and it may be responsible for the observed thrombosis.
